Accuray Incorporated Announces Pricing of Initial Public Offering
Accuray Incorporated Announces Pricing of Initial Public Offering
February 8, 2007 at 12:00 AM EST
SUNNYVALE, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Accuray
Incorporated (Nasdaq: ARAY) today announced the initial public offering of
16,000,000 shares of common stock, of which 10,000,000 are being sold by
the Company and 6,000,000 are being sold by certain stockholders of the
Company, at $18.00 per share. Accuray and the selling stockholders have
granted the underwriters an option to purchase up to an additional 399,998
and 2,000,000 shares, respectively, at the initial public offering price to
cover over-allotments, if any. The common stock will trade on the NASDAQ
Global Market under the symbol ARAY.
J.P. Morgan Securities Inc. and UBS Investment Bank are serving as joint book-running managers for the offering, with Piper Jaffray & Co. as lead manager and Jefferies & Company, Inc. as co-manager for the offering.
A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering is only being made by means of a prospectus. A final prospectus for the offering may be obtained from J.P. Morgan Securities Inc., Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, and UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York, NY 10171.
Accuray designs, develops and sells the CyberKnife(R) System, an intelligent robotic radiosurgery system designed to treat solid tumors anywhere in the body.
NOTE: Accuray, the Accuray logo and CyberKnife are among trademarks or registered trademarks of Accuray Incorporated.
SOURCE Accuray Incorporated
J.P. Morgan Securities Inc. and UBS Investment Bank are serving as joint book-running managers for the offering, with Piper Jaffray & Co. as lead manager and Jefferies & Company, Inc. as co-manager for the offering.
A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering is only being made by means of a prospectus. A final prospectus for the offering may be obtained from J.P. Morgan Securities Inc., Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, and UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York, NY 10171.
Accuray designs, develops and sells the CyberKnife(R) System, an intelligent robotic radiosurgery system designed to treat solid tumors anywhere in the body.
NOTE: Accuray, the Accuray logo and CyberKnife are among trademarks or registered trademarks of Accuray Incorporated.
SOURCE Accuray Incorporated